John M Oropello, MD
img_John M Oropello
PROFESSOR | Surgery
PROFESSOR | Medicine
Are you a patient?
Specialties
Critical Care
Research Projects Current:
\r\n\r\n
  • Kohli-Seth R, Oropello JM, Benjamin E, Manasia A, Leibowitz A, DelGiudice R, Hufanda J. A double blind, placebo-controlled, study of E5564, a lipid A antagonist, administered by twice daily intravenous infusions in patients with severe sepsis. \r\n\r\n
  • Benjamin E, Kohli-Seth R, Oropello JM, Leibowitz A, Manasia A, DelGiudice R, Hufanda J. Efficacy and safety of Drotrecogin (Alfa) in adult patients with early severe sepsis \r\n\r\n
  • Oropello JM, Kohli-Seth R, Benjamin E, Manasia A, Leibowitz A, DelGiudice R, Hufanda J. Central venous access techniques: successful cannulation of central veins upon withdrawal of needle vs. advancement. \r\n\r\n
  • Kohli-Seth R, Oropello JM, Benjamin E, Manasia A, Leibowitz A, DelGiudice R, Hufanda J. Resting energy expenditure in morbidly obese septic and non-septic patients \r\n\r\n
  • Oropello JM, Benjamin E, Manasia A, Kohli-Seth R, DelGiudice R, Hufanda J. A Phase 2 study to determine the efficacy of Sivelestat in patients with Acute Lung Injury \r\n\r\n
  • Benjamin E Kohli-Seth R, Oropello JM Manasia A, Hannon E, DelGiudice R, Hufanda J Benign postoperative hyperlactatemia in Neurosurgical Patients \r\n\r\n
  • Benjamin E, Oropello JM, Manasia A, Kohli-Seth R, DelGiudice R, Hufanda J. Beginning and Ending Supportive therapy (BEST) for the Kidney Study \r\n
  • Oropello JM, Benjamin E, Manasia A, Kohli-Seth R, DelGiudice R, Hufanda J. Phase 3 multicenter randomized placebo study of PHP in sepsis with Shock. \r\n\r\n
  • A Manasia, Benjamin E, Oropello JM, R. Kohli-Seth, R DelGiudice, J Hufanda. Limited transthoracic echocardiography (TTE) by non-cardiologist surgical intensivists. \r\n\r\n
  • Oropello JM, Benjamin E, Manasia A, R. Kohli-Seth, R DelGiudice, J Hufanda.. J4A-MC-EZZI. A phase 2b Study to determine the efficacy and safety of LY315920 in patients with severe sepsis. \r\n\r\n
  • S. Chhabra, Benjamin E, Oropello JM, Manasia A, Victor Murgolo, R DelGiudice, J Hufanda. Zeroing of hydraulic monitoring systems using laser guidance. \r\n\r\n
  • Benjamin E, Oropello JM, Manasia A, Altschuller-Felberg C, Hufanda J, DelGiudice R: Multicenter, Double Blind, Placebo Controlled, Randomized, Phase III Study of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor [rTFPA/SC-59735]) in Severe Sepsis. \r\n\r\n
  • Benjamin E Oropello JM. Nierman D, Loren S, Hufanda J, DelGiudice R. Prospective study of anemia of critical illness and transfusion is critically ill patients. \r\n\r\n
  • Leibowitz A, Benjamin E, Oropello JM, Manasia, A, DelGiudice R., A randomized, open-labeled, pilot assessment of the effect of Protonix IV for injection (Pantoprazole Sodium) on gastric pH in ICU patients. \r\n\r\n
  • Oropello JM, Benjamin E, Altschuller-Felberg C, DelGiudice R, Hufanda J. . Open-label, comparative, randomized multicenter Phase 111 study of iv Synercid vs.Vancomycin or Nafcillin in the treatment of 380 patients with central venous catheter-related bacteremia. \r\n\r\n
  • Manasia A, Oropello JM, Benjamin E, Altschuller-Felberg C, DelGiudice R A Phase II, Dose-Ranging Evaluation of Safety and Efficacy of a-hANP for ARDS. \r\n\r\n
  • Kohli-Seth, Benjamin E. Oropello JM, Manasia, DelGiudice R, Hufanda J Amede F. The effect of continuous veno-venous hemofiltration (CVVH) on lung water as measured by transthoracic impedance analysis (TBIA). \r\n\r\n
  • Oropello JM, Altschuller-Felberg C, Benjamin E, Manasia A, DelGuidice R: rSP-c surfactant for the treatment of acute respiratory distress syndrome (ARDS), a randomized, multicenter, parallel group, controlled pilot study. \r\n\r\n
  • Oropello JM, Manasia A, Benjamin E, Altschuller-Felberg C, DelGuidice R: A phase II study to determine the efficacy and safety of LY315920 in patients with severe sepsis. \r\n \r\n
  • Benjamin E, Oropello JM, Manasia A, Altschuller-Felberg C Hufanda, J: Multicenter, single blind, placebo-controlled, randomized, dose escalation study of recombinant tissue factor pathway inhibitor (rTFOI/SC-59735) in severe sepsis. \r\n
  • BA, Bernard Baruch College

    MD, St. George's University School of Medicine

    MD, St. George's University School of Medicine

    Coney Island Hospital

    Coney Island Hospital

    The Mount Sinai Hospital

    Residency, Internal Medicine, Coney Island Hospital

    Fellowship, Pulmonary Disease, Coney Island Hospital

    Fellowship, Critical Care Medicine, Mount Sinai Hospital

    Certifications

    American Board of Internal Medicine

    1990

    Fellow-of-the-Year Award Critical Care Fellowship

    The Mount Sinai Medical Center

    1989

    Consistent outstanding clinical performance during Internal Medicine Residency and Pulmonary Fellowship

    Coney Island Hospital

    1984

    The Abdool Islami Award for Overall Academic Excellence

    St. Georges' University, Grenada

    1978

    The President's Excellency Award for the

    Baruch College Honors Program, New York

    1978

    The Muriel Lee Winokur Biology Scholarship

    1978

    Magna Cum Laude with Honors in Biology

    Bernard Baruch College, New York, NY

    Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

    Dr. Oropello has not yet completed reporting of Industry relationships.

    Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.